US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Astria Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
Astria Stockholders Vote to Approve Acquisition by BioCryst
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS BCRX
News headline image
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS BCRX
News headline image
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Tickers ATXS
< Previous 1 2 3 4 Next >